Ken Mills, Regenxbio CEO
Regenxbio to seek accelerated approval of Hunter syndrome gene therapy using biomarker data
A Hunter syndrome gene therapy developed by Regenxbio significantly cut levels of a key biomarker associated with the disease, according to
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
